We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

A Promising Step Forward in Psoriasis Therapy

Robert S. Stern, MD
JAMA. 2003;290(23):3133-3135. doi:10.1001/jama.290.23.3133.
Text Size: A A A
Published online


About 4.5 million adults in the United States have psoriasis,1 a chronic, often uncomfortable and disfiguring disease typically lasting more than 30 years. Approximately half a million individuals find the disease a substantial problem in everyday life. Fewer than half of those affected by psoriasis find their treatment highly satisfactory.1

Although available treatment options for patients with severe psoriasis have changed little over nearly 20 years, psoriasis has recently become a focus for innovative therapies. With the development of monoclonal antibodies that alter immune function, 4 new products—2 antibodies that modulate T-cell functions (efalizumab and alefacept) and 2 tumor necrosis factor α inhibitors (infliximab and etanercept)—have demonstrated beneficial effects on moderate to severe psoriasis. In this issue of THE JOURNAL, Gordon et al2 report on the effect of efalizumab on psoriasis as measured by both physician and patient assessment. This and other studies demonstrate that efalizumab is superior to placebo.24 To determine the place of efalizumab in the current therapeutic armamentarium, however, its safety and efficacy must be determined relative to other therapies for severe psoriasis.



Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

24 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles